From the Globe and Mail:
One of the world's most costly cancer drugs will not be marketed in Canada because the distributor can't charge the price it wants -- one a federal board has found to be too high.
Bristol-Myers Squibb Canada has taken the unusual move of not launching the colorectal cancer drug Erbitux after it could not agree on a price with the Patented Medicine Prices Review Board. The drug was approved by Health Canada nine months ago. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment